Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial

Adrienne E Shapiro, Elias Sarkis, Jude Acloque, Almena Free, Yaneicy Gonzalez-Rojas, Rubaba Hussain, Erick Juarez, Jaynier Moya, Naval Parikh, David Inman, Deborah Cebrik, Ahmed Nader, Nadia Noormohamed, Qianwen Wang, Andrew Skingsley, Daren Austin, Amanda Peppercorn, Maria L Agostini, Sergio Parra, Sophia Chow, Erik Mogalian, Phillip S Pang, David K Hong, Jennifer E Sager, Wendy W Yeh, Elizabeth L Alexander, Leah A Gaffney, Anita Kohli

Open source

DOI
10.1093/ofid/ofad354
Published
2023-07-14
Container
Open Forum Infectious Diseases
Publisher
Oxford University Press (OUP)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/ofid/ofad354,
  title = {Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial},
  author = {Adrienne E Shapiro and Elias Sarkis and Jude Acloque and Almena Free and Yaneicy Gonzalez-Rojas and Rubaba Hussain and Erick Juarez and Jaynier Moya and Naval Parikh and David Inman and Deborah Cebrik and Ahmed Nader and Nadia Noormohamed and Qianwen Wang and Andrew Skingsley and Daren Austin and Amanda Peppercorn and Maria L Agostini and Sergio Parra and Sophia Chow and Erik Mogalian and Phillip S Pang and David K Hong and Jennifer E Sager and Wendy W Yeh and Elizabeth L Alexander and Leah A Gaffney and Anita Kohli},
  year = {2023},
  journal = {Open Forum Infectious Diseases},
  doi = {10.1093/ofid/ofad354},
  url = {https://doi.org/10.1093/ofid/ofad354}
}

RIS

TY  - JOUR
TI  - Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial
AU  - Adrienne E Shapiro
AU  - Elias Sarkis
AU  - Jude Acloque
AU  - Almena Free
AU  - Yaneicy Gonzalez-Rojas
AU  - Rubaba Hussain
AU  - Erick Juarez
AU  - Jaynier Moya
AU  - Naval Parikh
AU  - David Inman
AU  - Deborah Cebrik
AU  - Ahmed Nader
AU  - Nadia Noormohamed
AU  - Qianwen Wang
AU  - Andrew Skingsley
AU  - Daren Austin
AU  - Amanda Peppercorn
AU  - Maria L Agostini
AU  - Sergio Parra
AU  - Sophia Chow
AU  - Erik Mogalian
AU  - Phillip S Pang
AU  - David K Hong
AU  - Jennifer E Sager
AU  - Wendy W Yeh
AU  - Elizabeth L Alexander
AU  - Leah A Gaffney
AU  - Anita Kohli
PY  - 2023
JO  - Open Forum Infectious Diseases
DO  - 10.1093/ofid/ofad354
UR  - https://doi.org/10.1093/ofid/ofad354
ER  - 

APA

Shapiro, A. E., Sarkis, E., Acloque, J., Free, A., Gonzalez-Rojas, Y., Hussain, R., Juarez, E., Moya, J., Parikh, N., Inman, D., Cebrik, D., Nader, A., Noormohamed, N., Wang, Q., Skingsley, A., Austin, D., Peppercorn, A., Agostini, M. L., Parra, S., Chow, S., Mogalian, E., Pang, P. S., Hong, D. K., Sager, J. E., Yeh, W. W., Alexander, E. L., Gaffney, L. A., & Kohli, A. (2023). Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial. Open Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofad354

Source records